Clinical Trials
35 trialsNCT04799275 2026-05-13
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05413018 2026-04-28
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
NCT05141682 2026-03-03
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT05197426 2026-02-11
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT05209295 2026-01-12
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Bristol-Myers Squibb
Phase 1 Terminated
NCT02512172 2025-12-03
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT04174196 2025-12-02
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02546986 2025-08-08
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Celgene
Phase 2 Completed
NCT01757535 2025-07-08
QUAZAR AML-001
Celgene
Phase 3 Completed
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT06022003 2025-03-24
OGILAR
French Innovative Leukemia Organisation
Phase 2 Recruiting
NCT04778410 2025-03-20
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Gilead Sciences
Phase 2 Terminated
NCT03450343 2024-10-28
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Medical University of South Carolina
Phase 1 Completed
NCT02250326 2024-09-19
abound2L+
Celgene
Phase 2 Completed
NCT03703375 2024-07-08
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Celgene
Phase 3 Active not recruiting
NCT03493646 2024-05-28
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Kirby Institute
Phase 2 Completed
NCT04722601 2024-05-16
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
University of Chicago
Phase 1/2 Terminated
NCT04173533 2024-05-14
AMADEUS
University of Birmingham
Phase 3 Active not recruiting
NCT04887857 2024-02-12
OMNIVERSE
Celgene
Phase 1 Completed
NCT06180863 2023-12-26
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Yale University
Phase 2 Withdrawn
NCT04639843 2022-11-04
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01845805 2022-10-04
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02900560 2022-06-10
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Translational Research in Oncology
Phase 2 Terminated
NCT02811497 2021-04-01
METADUR
University Health Network, Toronto
Phase 2 Completed
NCT03723135 2020-09-18
Expanded Access for CC-486
Celgene
Approved for marketing
NCT02343536 2020-08-28
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
Celgene
Phase 1 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT01478685 2019-11-12
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
Phase 1 Completed
NCT00528983 2019-11-08
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Celgene
Phase 1 Completed
NCT02374099 2018-12-14
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Celgene
Phase 2 Terminated
NCT02269943 2018-12-12
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
Phase 2 Completed
NCT01835587 2018-11-20
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Celgene
Phase 1/2 Completed
NCT01908387 2015-07-28
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Phase 1 Terminated